The first-of-its-kind blood test predicts an individual patient's therapeutic response to checkpoint-inhibitor immunotherapy.
EpiSwitch CiRT provides patient specific guidance to support informed decision-making regarding the treatment plan you create for your patient.
Benefits of EpiSwitch CiRT
Understand your patient's likelihood of response to guide your decisions on beginning or continuing treatment with an ICI
Among patients experiencing an adverse reaction or toxicity, use the test to identify those who are likely to benefit from continued treatment
Improve overall patient response rate by accurately stratifying patients based on their likelihood of response
of a patient's personalized probability of response.
With a routine qPCR blood test, our comprehensive and validated approach
delivers an easy-to-understand, confidential report that includes a prediction
of individual patient response, with no need for a biopsy.
Patients with a positive EpiSwitch CiRT result can begin or continue their
Built on Oxford BioDynamics' EpiSwitch technology platform, CiRT is based on a comprehensive and validated approach that identifies and stratifies critical drivers of an individual's immune system.
EpiSwitch CiRT Report
Individuals with a response level in the high probability range have a greater chance of benefiting from an ICI. Conversely, individuals with a response level in the low probability range have a reduced chance of benefiting from an ICI. These results should be considered along with other clinical features for interpretation by a licensed medical professional.
The EpiSwitch CiRT report includes indications for a healthcare professional to interpret a patient's likelihood of response to ICI therapy and formulate an effective management plan.